216 related articles for article (PubMed ID: 33674268)
1. Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
Surapaneni S; Yerramilli U; Bai A; Dalvie D; Brooks J; Wang X; Selkirk JV; Yan YG; Zhang P; Hargreaves R; Kumar G; Palmisano M; Tran JQ
Drug Metab Dispos; 2021 May; 49(5):405-419. PubMed ID: 33674268
[TBL] [Abstract][Full Text] [Related]
2. In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors.
Selkirk JV; Yan YG; Ching N; Paget K; Hargreaves R
Eur J Pharmacol; 2023 Feb; 941():175442. PubMed ID: 36470447
[TBL] [Abstract][Full Text] [Related]
3. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Tran JQ; Zhang P; Ghosh A; Liu L; Syto M; Wang X; Palmisano M
Adv Ther; 2020 Oct; 37(10):4381-4395. PubMed ID: 32857315
[TBL] [Abstract][Full Text] [Related]
4. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
[TBL] [Abstract][Full Text] [Related]
5. Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
Tran JQ; Zhang P; Walker S; Ghosh A; Syto M; Wang X; Harris S; Palmisano M
Adv Ther; 2020 Dec; 37(12):4944-4958. PubMed ID: 33025342
[TBL] [Abstract][Full Text] [Related]
6. Investigation into MAO B-Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (
Bai A; Shanmugasundaram V; Selkirk JV; Surapaneni S; Dalvie D
Drug Metab Dispos; 2021 Aug; 49(8):601-609. PubMed ID: 34011531
[TBL] [Abstract][Full Text] [Related]
7. Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
Briggs E; Chapel S; Zhang P; Palmisano M; Tran JQ
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):119-126. PubMed ID: 33314790
[TBL] [Abstract][Full Text] [Related]
8. Ozanimod: First Approval.
Lamb YN
Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738
[TBL] [Abstract][Full Text] [Related]
9. Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.
Tran JQ; Hartung JP; Tompkins CA; Frohna PA
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):634-640. PubMed ID: 29125718
[TBL] [Abstract][Full Text] [Related]
10. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
Harris S; Tran JQ; Southworth H; Spencer CM; Cree BAC; Zamvil SS
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32737072
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L;
Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
[TBL] [Abstract][Full Text] [Related]
12. An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.
Fronza M; Lorefice L; Frau J; Cocco E
Drug Des Devel Ther; 2021; 15():1993-2004. PubMed ID: 34007159
[TBL] [Abstract][Full Text] [Related]
13. Ozanimod (Zeposia) for multiple sclerosis.
Med Lett Drugs Ther; 2020 Aug; 62(1605):132-134. PubMed ID: 32970043
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
[TBL] [Abstract][Full Text] [Related]
16. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
[TBL] [Abstract][Full Text] [Related]
17. Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P
Boof ML; van Lier JJ; English S; Fischer H; Ufer M; Dingemanse J
Xenobiotica; 2020 Aug; 50(8):947-956. PubMed ID: 32105166
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
[TBL] [Abstract][Full Text] [Related]
19. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
Kuczynski AM; Oh J
Neurodegener Dis Manag; 2021 Jun; 11(3):207-220. PubMed ID: 34011158
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
Armuzzi A; Cross RK; Lichtenstein GR; Hou J; Deepak P; Regueiro M; Wolf DC; Akukwe L; Ahmad HA; Jain A; Kozinn M; Wu H; Petersen A; Charles L; Long M
Clin Gastroenterol Hepatol; 2024 May; 22(5):1067-1076.e3. PubMed ID: 38040274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
